These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 19455662)

  • 1. Strategies for drug-eluting stent treatment of bifurcation coronary artery disease in the United States: insights from the e-Cypher S.T.L.L.R.trial.
    Suzuki N; Angiolillo DJ; Tannenbaum MA; Driesman MH; Smith C; Bikkina M; Meckel CR; Morales CE; Xenopoulos NP; Coletta JE; Bezerra HG; Bass TA; Costa MA
    Catheter Cardiovasc Interv; 2009 Jun; 73(7):890-7. PubMed ID: 19455662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
    Stella PR; Belkacemi A; Dubois C; Nathoe H; Dens J; Naber C; Adriaenssens T; van Belle E; Doevendans P; Agostoni P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1138-46. PubMed ID: 22422607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of stenting strategy in true coronary artery bifurcation lesions.
    Lin QF; Luo YK; Lin CG; Peng YF; Zhen XC; Chen LL
    Coron Artery Dis; 2010 Sep; 21(6):345-51. PubMed ID: 20613498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term clinical and angiographic outcomes after implantation of sirolimus-eluting stents with a "modified mini-crush" technique in coronary bifurcation lesions.
    Yang HM; Tahk SJ; Woo SI; Lim HS; Choi BJ; Choi SY; Yoon MH; Park JS; Zheng M; Hwang GS; Kang SJ; Shin JH
    Catheter Cardiovasc Interv; 2009 Jul; 74(1):76-84. PubMed ID: 19360861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach.
    Burzotta F; Trani C; Todaro D; Mariani L; Talarico GP; Tommasino A; Giammarinaro M; Niccoli G; Porto I; Leone AM; Mongiardo R; Mazzari MA; Schiavoni G; Crea F
    JACC Cardiovasc Interv; 2011 Mar; 4(3):327-35. PubMed ID: 21435612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventional therapy of bifurcation lesions: a TIMI flow-guided concept to treat side branches in bifurcation lesions--a prospective randomized clinical study (Thueringer bifurcation study, THUEBIS study as pilot trial).
    Korn HV; Yu J; Ohlow MA; Huegl B; Schulte W; Wagner A; Wassmer G; Gruene S; Petek O; Lauer B
    Circ Cardiovasc Interv; 2009 Dec; 2(6):535-42. PubMed ID: 20031771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of coronary bifurcation stenting with the crush versus the culotte technique using sirolimus eluting stents: the Nordic stent technique study.
    Erglis A; Kumsars I; Niemelä M; Kervinen K; Maeng M; Lassen JF; Gunnes P; Stavnes S; Jensen JS; Galløe A; Narbute I; Sondore D; Mäkikallio T; Ylitalo K; Christiansen EH; Ravkilde J; Steigen TK; Mannsverk J; Thayssen P; Hansen KN; Syvänne M; Helqvist S; Kjell N; Wiseth R; Aarøe J; Puhakka M; Thuesen L;
    Circ Cardiovasc Interv; 2009 Feb; 2(1):27-34. PubMed ID: 20031690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
    Garg S; Serruys P; Onuma Y; Dorange C; Veldhof S; Miquel-Hébert K; Sudhir K; Boland J; Huber K; Garcia E; te Riele JA;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1190-8. PubMed ID: 20129545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Leon MB; Kandzari DE; Mauri L; Edwards R; Kong DF; Cowper PA; Anstrom KJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1199-207. PubMed ID: 20129546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results.
    Kervinen K; Niemelä M; Romppanen H; Erglis A; Kumsars I; Maeng M; Holm NR; Lassen JF; Gunnes P; Stavnes S; Jensen JS; Galløe A; Narbute I; Sondore D; Christiansen EH; Ravkilde J; Steigen TK; Mannsverk J; Thayssen P; Hansen KN; Helqvist S; Vikman S; Wiseth R; Aarøe J; Jokelainen J; Thuesen L;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1160-5. PubMed ID: 24262616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry.
    Toyofuku M; Kimura T; Morimoto T; Hayashi Y; Shiode N; Nishikawa H; Nakao K; Shirota K; Kawai K; Hiasa Y; Kadota K; Nozaki Y; Isshiki T; Sone T; Mitsudo K;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):654-63. PubMed ID: 23866178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
    Onuma Y; Kukreja N; Daemen J; Garcia-Garcia HM; Gonzalo N; Cheng JM; van Twisk PH; van Domburg R; Serruys PW;
    JACC Cardiovasc Interv; 2009 Jul; 2(7):603-10. PubMed ID: 19628181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of zotarolimus- versus everolimus-eluting stents in the treatment of coronary bifurcation lesions.
    Herrador JA; Fernandez JC; Guzman M; Aragon V
    Catheter Cardiovasc Interv; 2011 Dec; 78(7):1086-92. PubMed ID: 21793165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.
    Garg S; Serruys PW; Silber S; Wykrzykowska J; van Geuns RJ; Richardt G; Buszman PE; Kelbæk H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Van Remortel E; Ronden J; Windecker S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):432-41. PubMed ID: 21511223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resolute zotarolimus-eluting stent to treat bifurcated lesions according to the provisional technique: a procedural performance comparison with sirolimus- and everolimus-eluting stents.
    Burzotta F; Trani C; Talarico GP; Tommasino A; Todaro D; Coluccia V; Pirozzolo G; Niccoli G; Leone AM; Porto I; Schiavoni G; Crea F
    Cardiovasc Revasc Med; 2013; 14(3):122-7. PubMed ID: 23453789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute procedural and six-month clinical outcome in patients treated with a dedicated bifurcation stent for left main stem disease: the TRYTON LM multicentre registry.
    Magro M; Girasis C; Bartorelli AL; Tarantini G; Russo F; Trabattoni D; D'Amico G; Galli M; Gómez Juame A; de Sousa Almeida M; Simsek C; Foley D; Sonck J; Lesiak M; Kayaert P; Serruys PW; van Geuns RJ
    EuroIntervention; 2013 Mar; 8(11):1259-69. PubMed ID: 23538155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty).
    Spaulding C; Teiger E; Commeau P; Varenne O; Bramucci E; Slama M; Beatt K; Tirouvanziam A; Polonski L; Stella PR; Clugston R; Fajadet J; de Boisgelin X; Bode C; Carrié D; Erglis A; Merkely B; Hosten S; Cebrian A; Wang P; Stoll HP; Henry P
    JACC Cardiovasc Interv; 2011 Jan; 4(1):14-23. PubMed ID: 21251624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
    Novack V; Cutlip D; Kleiman N; Pencina M; Mauri L; Yen CH; Berger P; Goldberg S; Kellett M; Waksman R; Hong M; Raizner AE; Cohen DJ
    JACC Cardiovasc Interv; 2009 Aug; 2(8):767-75. PubMed ID: 19695546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug eluting stenting in bifurcation coronary lesions long-term results applying a systematic treatment strategy.
    Assali AR; Vaknin-Assa H; Lev E; Teplitsky I; Dvir D; Brosh D; Bental T; Battler A; Kornowski R
    Catheter Cardiovasc Interv; 2012 Mar; 79(4):615-22. PubMed ID: 22162218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.